Company intelligence / Profile preview
Allertein Therapeutics, LLC
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed a Phase 1 clinical trial (NCT00850668) for EMP-123, a peanut allergy vaccine consisting of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins. The trial evaluated safety and side effects in healthy volunteers and peanut-allergic participants.
- Therapeutic areas
- Immunology
- Modalities
- VaccinesRecombinant modified proteins
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institute of Allergy and Infectious Diseases
Beyond the preview
Go deeper on Allertein Therapeutics, LLC.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allertein Therapeutics, LLC.